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Azadirachta indica, popularly known as ‗Neem‘, is an important plant in the Ayurveda system of medicine. It is known 
to prevent about at least 40 types of diseases in home-practice. A previous report showed that the methanolic extract of this 
plant can effectively control proliferation of leukemia cells. Here, we explored the eEthanolic extract dried neem leaves for a 
new molecule with potent anti-leukemic property.Four biomolecules were isolated viz. rutin, isoquercetin, quercetrin and β-
sitosterol-3-O-β-D-glucoside from the ethanolic extract by repeated column chromatography and HPLC.Quercetrin 
structures of the isolated molecules were confirmed by Mass, 1HNMR, 13C NMR spectra analysis. MTT assay revealed that 
β-sitosterol-3-O-β-D-glucosideeffectively reduced the proliferation of MOLT 4 leukemic cells in a dose and time dependent 
manner. DAPI staining with confocal microscopy indicated that β-sitosterol-3-O-β-D-glucoside efficiently induced nuclear 
DNA fragmentation in MOLT 4 cells. Finally, flow cytometry after PI staining showed that the compound has potential to 
check the cell cycle progression at sub G1 phase. With the available results, it can be concluded that β-sitosterol-3-O-β-D-
glucoside has potential to be good therapeutic drug in leukemia treatment. 
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Leukemia continues to be an enigmatic challenge to 
cancer biologists and medical practitioners. Several 
claims have been made time to time for discovering 
sure molecules of leukemia, yet a dependable cure 
against leukemia remains a challenge. The primary 
reason for this is the multiple survival pathways
1,2
 
adopted by the leukemic cells by carrying mutations 
in their genome, which ensures up-regulation of anti-
apoptotic proteins
3
 (e.g. Bcl-2, Bcl-XL etc.) and 
down-regulation of pro-apoptotic proteins
4
 (e.g. Bid, 
Bim etc.) that ultimately reduces the apoptotic events. 
Therefore multi-target drugs toeradicate these 
neoplastic blood cells with minimum side-effects are 
required. In recent years certain anti-leukemic herbal 
products, and ethanol-medicines have drawn keen 
attention of researchers because of their multiple 
targets and least side-effects. 
Azadirachta indica (Neem), a member of the 
Meliaceae family, is commonly found in tropical 
countries e.g. India, Bangladesh, Nepal, Pakistan and 
African countries as well. Neem is an evergreen tree 
with wide spectra of biological activities. The tree is 
regarded as ‗village dispensary‘ in India. Neem has 
been extensively used in Ayurveda, Unani and 
homeopathic medicine and has become a cynosure of 
modern medicine in different disease management
5
. 
In East Africa, this tree is called as Mwarobaini, 
which means ―the tree of the 40‖ indicates its use for 
the treatment of 40 types of diseases. The entire plant 
is of therapeutic values as it is a complex a high 
number of bioactive ingredients including Nimbin, 
nimbidin, nimbolide, azadirachtin, different limonoids, 
flavonoids, etc. Such ingredients play vital role in 
disease management by modulating different genetic 
pathways
6-8
. Numerous biological and pharmacological 
activities of this plant have been reported  
earlier, including antifungal
9
, antibacterial
10
, and  
anti-inflammatory
6
, anti-arthritic
11
, anti-pyretic
12
, 
hypoglycemic
13
, anti-gastric ulcer
14
 and anti-tumor
15,16 
etc. Anti-carcinogenic properties has been demonstrated 
by the leaves and its components of Azadirachta 
indica
17
. The main objective of this work was to search 
out novel anti-leukemic molecules. In the present 
article, we approached to isolate biomolecules from 
the leaves and thoroughly screened against leukemic 
cell lines. One of the isolated biomolecules, showed 
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*Correspondence:  
Phone: +91-9874192648 (Mob);  
Fax: +91 3323546623 
E-mail: spaul_1971@yahoo.com 
INDIAN J. BIOCHEM. BIOPHYS., VOL. 57, FEBRUARY 2020 
 
 
28 
anti-proliferative and nuclear deformation activity 
against leukemic cells. 
 
Materials and Methods 
 
Chemicals 
RPMI 1640 and fetal bovine serum (FBS) were 
purchased from GIBCO/Invitrogen. Penicillin, 
streptomycin, DAPI, and thiazolyl blue tetrazolium 
bromide were purchased from SIGMA. Silica gel 
(100-200) and all the solvents used for column 
chromatography and HPLC were purchased from 
Merck, India. 
 
Collection of plant materials 
The leaves were collected from mature tree located 
in the Garmirjapur village of West Bengal during the 
August - October of 2014. The leaves were air dried 
at 35-40C temperature for several days. Dried 
samples were ground into fine powder (250 g) and 
stored in vacuum desiccators until use. 
 
Extraction and isolation of the compounds 
Plant sample was extracted with methanol at room 
temperature for 3 days. This step was repeated twice. 
Liquid portion was filtered the extracted through 
Whatman filter paper and evaporated to dryness in a 
rotary evaporator (~50 g). Dried extract was fractioned 
into hexane and butanol-water (3:1). Butanol fraction 
was evaporated to dryness in a rotary evaporator  
(~10 g). Dried extract was loaded in a silica gel  
(100-200 mesh) column using chloroform-methanol 
solvent system. Fraction 3 and 4 were mixed up and 
further chromatographed on a silica gel column using 
chloroform: methanol (93-90:7-10) solvent system to 
yield compound β-sitosterol-3-O-β-D-glucoside. 
Fraction 7, 8 and 9 were mixed up and further 
chromatographed on silica gel column using  
chloroform: methanol (90-85:10-15) solvent system to 
yield compound isoquercetin and a mixture of 
isoquercetin and quercetrin. Fraction 10 was further 
chromatographed on silica gel column using chloroform: 
methanol (75-70:25-30) solvent system to yield 
compound rutin. Compounds isolated, were identified 
by analyzing their spectra (mass and NMR). 
 
High performance liquid chromatography (HPLC) 
The mixture containing compound Quercetrin was 
subjected to Preparative HPLC (Waters). Major 
compound Quercetrin present in this mixture was 
purified using Xtera C-18 preparative column and 
solvent system was methanol (40): water (59.5): acetic 
acid (0.5), a flow rate 20 mL/min, runtime 35 min. 
Compound quercetrin was amorphous, yellow powder.  
Cell culture 
Human leukemic cell lines MOLT 4 and U937 
were maintained in RPMI 1640 media supplemented 
with 10% heat-inactivated fetal bovine serum (FBS), 
100 U/mL penicillin and 100 μg/mL streptomycin at 
37°C in a humidified atmosphere of 5% CO2. 
 
MTT assay 
Cells were seeded at a density 1 × 10
5
 cells/well in 
96-well microtitre plate and treated with each 
compound at different concentrations for 24 h and  
48 h time points. After treatment, 20 μL of 5 mg/mL 
MTT solution was added to each well and incubated 
for 4 h at 37°C. After incubation, the medium was 
aspirated and for mazan crystals produced in cells 
were solubilized in dimethylsulfoxide. Absorbance 
was measured at 570 nm using a microplate reader 
(iMark, Bio-Rad, Japan). Results were expressed as a 
percentage of control. 
 
DAPI nuclear staining 
Cells were seeded at a density 1 × 10
5
 cells/well in 
96-well microtitre plate and treated with β-sitosterol-
3-O-β-D-glucoside at different concentrations for 24 h. 
After treatment, cells were collected, washed with 
phosphate buffered saline (PBS) and permeabilized 
with methanol. DAPI (1 μg/mL in PBS) was added 
and incubated for 15 min at room temperature and 
observed under a confocal microscope (Olympus). 
 
Cell cycle analysis 
Actively growing U937 and MOLT 4 cells were 
treated with β-sitosterol-3-O-β-D-glucoside for 24 h 
time points, then washed, harvested, fixed by 70% 
ethanol and incubated for 30 min in PBS containing 
100 µg/mL RNase and 50 µg/mL propidium iodide 
(PI). 1 × 10
4
 cells were analyzed for each sample on a 
flow cytometer. Results were expressed as the 
percentage of cells in each phase of the cell cycle. 
 
Results 
 
Characterization of the isolated compounds 
Structures of the isolated compounds were 
determined by analyzing the spectral data, e.g. mass 
spectrum, 
1
H NMR and 
13
C NMR. Spectral data of the 
isolated compounds were compared with the 
previously reported data which was almost same with 
the previously reported data and confirmed the 
isolated bio-molecules asquercetin-3-O-rutinoside (rutin), 
a flavone-rutinoside, molecular weight 610, amorphous, 
yellow powder, yielded ~ 350 mg. (0.14%); Quercetin-3-
O-β-D-glucopyranoside (isoquercetin), a flavone-
glycoside, molecular weight 464, amorphous, yellow 
SARKAR et al.: ANTI-LEUKEMIC BIOMOLECULES OF AZADIRACHTA INDICA 
 
 
29 
powder, yielded ~ 60 mg (0.024%); quercetin-3-O-α-L-
rhamnoside (quercetrin), a flavone-rhamnoside, 
molecular weight of 448, amorphous, yellow powder, 
yielded ~ 40 mg (0.016%); β-sitosterol-3-O-β-D-
glucoside, molecular weight 576, white powder, yielded 
~ 20 mg (0.008%). Rutin, isoquercetin, quercetrin all 
have a flavonoid backbone with links sugar moiety 
except β-sitosterol-3-O-β-D-glucoside which is a 
steroidal glycoside (Fig. 1). Rutin is a ubiquitous 
flavonoid found in plants
18
. 
 
Differential anti-proliferative activity of β-sitosterol-3-O-β-D-
glucosideagainst leukemic cells 
To investigate the anti-leukemic properties of the 
isolated bio-molecules, we performed the MTT assay. 
U937 and MOLT 4 cells were treated with each 
compound for 24 and 48 h. The result of this assay 
showed that isolated bio-molecules have differential anti-
proliferative actions. Compound rutin, isoquercetin, 
quercetrinremained inactive after treatment to the cell 
lines and did not show any anti-proliferative activity, 
rather isoquercetin accelerate the proliferation of both the 
cell lines tested. β-sitosterol-3-O-β-D-glucoside, a 
steroidal glycoside, effectively blocked the proliferation 
of leukemic cells MOLT 4 with IC50 (Fig. 2A) value 
 
 
Fig. 2 — Assessment of anti-proliferative activity of the isolated compounds against (I) MOLT 4 cells; (II) U937 cells; and (III) normal PBMC. 
Cells were treated with each individual compound (Rutin, Isoquercetin, Quercetrin and β-sitosterol-3-O-β-D-glucoside) at different dose for 24 h 
(A) and 48 h (B) time points. After incubation, MTT assay was performed to evaluate the anti-proliferative capacity. Each bar graph represents 
Mean ± SD of three independent experiments 
 
 
Fig. 1 — Structures of the isolated biomolecules from 
Azadirachta indica.Rutin: Quercetin-3-O-rutinoside, Isoquercetin: 
Quercetin-3-O-β-D-glucopyranoside, Quercetrin: Quercetin-3-O-
α-L-rhamnoside, β-sitosterol-3-O-β-D-glucoside 
INDIAN J. BIOCHEM. BIOPHYS., VOL. 57, FEBRUARY 2020 
 
 
30 
below 40 µM. This anti-proliferative activity was  
dose-dependent and time-dependent and cell specific, as 
β-sitosterol-3-O-β-D-glucoside did not show any 
cytotoxic activity against U937 cells (Fig. 2B). We also 
tested the cytotoxic activity of these bio-molecules against 
normal Peripheral Blood Mononuclear Cells (PBMC) and 
found that none of these isolated compounds showed any 
cytotoxicity against PBMCs (Fig. 2C). 
 
β-sitosterol-3-O-β-D-glucosideinduced nuclear deformation 
and fragmentation in MOLT 4 Cells 
Nuclear DNA fragmentation is one of the hallmark 
events of apoptosis. Therefore, to be assured about the 
apoptotic activity of β-sitosterol-3-O-β-D-glucoside, 
we treated the MOLT 4 cells with β-sitosterol-3-O-β-
D-glucosideat IC50 values for 24 h and then stained 
with DAPI and observed under fluorescent 
microscope. We found that β-sitosterol-3-O-β-D-
glucoside effectively increased the number of 
fragmented and deformed nuclei after treatment as 
compared to control set (Fig. 3). 
 
β-sitosterol-3-O-β-D-glucosideincreased sub-G1cell population 
of MOLT 4 cells 
Cell cycle analysis of the treated MOLT 4 cells 
indicated that, β-sitosterol-3-O-β-D-glucoside effective 
increased the Sub-G1 cell population after 24 h of 
treatment (Fig. 4) which further establish the apoptotic 
potential of the β-sitosterol-3-O-β-D-glucoside. At IC50 
values, about 54% cells arrested at the Sub-G1 phase of 
the cell cycle as compared to control set. 
 
Discussion 
Four bio-molecules has been isolated from the neem 
tree and their structures were determined by comparing 
the spectral data with previously reported data. Here 
we have investigated the four isolated bio molecules 
against two leukemic cells U937 and MOLT4 for their 
anti-proliferative potentiality. The result of the  
MTT assay indicated that out of four compounds tested, 
β-sitosterol-3-O-β-D-glucoside showed prominent 
cytotoxic activity against MOLT 4 cells but not against 
U937. Anti-proliferative activity in MOLT 4 cells was 
 
 
Fig. 3 — Detection of nuclearfragmentation by DAPI staining 
after β-sitosterol-3-O-β-D-glucoside treatment. MOLT 4 cells 
were treated with β-sitosterol-3-O-β-D-glucoside for 24 h. After 
that, nuclear DNA was stained with DAPI and cells were 
observed under fluorescent microscope.MOLT 4 cells showeda 
high degree of nuclear fragmentation 
 
 
Fig. 4 — Cell cycle analysis of MOLT 4 cell line post β-sitosterol-
3-O-β-D-glucoside treatment. MOLT 4 cells were treated with  
β-sitosterol-3-O-β-D-glucoside for 24 h and DNA was stained with 
propidium iodide and analyzed ona flow cytometer 
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dose and time dependent. All other isolated compounds 
did not show noticible anti-proliferaive effect. 
Isoquercetin showed proliferative activity in a dose 
dependent manner to both the cell lines tested. In  
this work we observed that the novel compound  
β-sitosterol-3-O-β-D-glucoside is much more effective 
against MOLT4 cell line which is a robust drug 
resistant cell line
19. On the other hand β-sitosterol-3-O-
β-D-glucoside showed minimal anti-proliferative effect 
against normal PBMC. It can be concluded that  
β-sitosterol-3-O-β-D-glucoside is a potent anti-leukemic 
agent that holds a great promise as a future drug in 
combating leukemia. 
 
 
The nuclear DNA breakdown is an event associated 
with the cellular apoptosis
20
. To be assured about  
the apoptotic efficacy of β-sitosterol-3-O-β-D-glucoside 
against MOLT 4 cells, we investigated nuclear DNA 
breakdown event by DAPI staining. We found  
that at IC50, β-sitosterol-3-O-β-D-glucoside effectively 
increased the number of deformed and fragmented 
nuclei in the treated MOLT 4 cells. A number of cellular 
proteins, e.g. DFF, ICAD/CAD, endonuclease G, are 
associated with nuclear DNA breakdown
21
. Therefore, 
further studies will help to reveal the molecular 
mechanism hidden behind this observation. 
 
Cell cycle analysis indicates that cells, those are 
arrested at Sub G0/G1 phase, undergo apoptosis
22
. Most 
of the chemotherapeutic drugs possess this potential
23
. 
Therefore, we studied cell cycle progression of MOLT 4 
after compound treatments. We found that about 54% 
cells arrested at sub-G1 phase and most of the G0-G1 cell 
population shifted to apoptotic population, which further 
establishes the apoptotic potential of the β-sitosterol- 
3-O-β-D-glucoside. However, the detail mechanism of 
cell cycle arrest needs to be studied in the future. 
 
β-sitosterol-3-O-β-D-glucoside is a steroidal 
glycoside which has shown appreciable antiproliferative 
activity against MOLT 4 cells. According to previous 
reports, β-sitosterol-3-O-β-D-glucopyranoside which 
is structurally very close to β-sitosterol-3-O-β-D-
glucoside selectively inhibited the activity of 
mammalian DNA polymerase λ24. Pol λ is a member 
of X family of DNA polymerase which performs  
a significant role in DNA repair mechanisms  
through resynthesizing missing nucleotides during  
non–homologous end joining during DNA double 
strand break. Hence, the antiproliferative activity may 
be achieved through several pathways including 
inhibiting the activity of DNA polymerase λ. Hence, 
blocking the DNA repair mechanism as well. 
Conclusion 
This study provides evidence for the therapeutic 
effectiveness of a novel molecule which can 
effectively block leukemia proliferation in vitro. It 
can efficiently increase Sub-G1 population and 
fragmented nuclei in MOLT 4 cells. Further, 
molecular studies are required to understand the 
mechanism for this β-sitosterol-3-O-β-D-glucoside 
mediated cellular toxicity. 
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